VAR - Varian Medical Systems, Inc.

NYSE - NYSE Delayed Price. Currency in USD
135.36
+0.51 (+0.38%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close 134.85
Open 134.48
Bid 135.35 x 900
Ask 135.36 x 1100
Day's Range 134.48 - 135.89
52 Week Range 101.42 - 142.50
Volume 354,223
Avg. Volume 546,858
Market Cap 12.31B
Beta (3Y Monthly) 0.94
PE Ratio (TTM) 32.89
EPS (TTM) N/A
Earnings Date N/A
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date 1998-12-02
1y Target Est N/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • PR Newswire 8 days ago

    Varian to Showcase Cancer Care Systems and Software at AAPM 2019

    PALO ALTO, Calif. , July 11, 2019 /PRNewswire/ -- Varian (NYSE: VAR) today announced it will be showcasing systems and software from its cancer care portfolio, including the IDENTIFY ™ Guidance System, ...

  • PR Newswire 10 days ago

    Cyclotron for Varian ProBeam Compact Proton Therapy System Installed at King Chulalongkorn Memorial Hospital, Bangkok, Thailand

    Her Royal Highness Princess Maha Chakri Sirindhorn Presided Over Rigging Ceremony PALO ALTO, Calif. , July 9, 2019 /PRNewswire/ -- Varian (NYSE: VAR) celebrated the installation of the cyclotron for its ...

  • PR Newswire 11 days ago

    Varian Provides TrueBeam System for IAEA Dosimetry Laboratory in Austria

    PALO ALTO, Calif. , July 8, 2019 /PRNewswire/ -- Varian (NYSE: VAR) is working in partnership with the International Atomic Energy Agency (IAEA) to improve cancer treatment by helping hospitals around ...

  • PR Newswire 17 days ago

    Varian to Expand Interventional Oncology Portfolio with Purchase of Embolic Bead Asset

    PALO ALTO, Calif., July 2, 2019 /PRNewswire/ -- Varian (VAR) today announced it has signed an asset purchase agreement to acquire the Boston Scientific portfolio of drug-loadable microsphere and bland embolic bead products for treating arteriovenous malformations and hypervascular tumors. When completed, this acquisition, in combination with the recent acquisitions of Endocare and Alicon, will expand Varian's portfolio of multidisciplinary integrated cancer care solutions. Varian's planned acquisition of the Boston Scientific portfolio of drug-loadable microsphere (Oncozene/Embozene Tandem) and bland embolic (Embozene) bead products will enable Varian to extend its new interventional oncology platform, and the Company will benefit from the products' regulatory clearances in more than 35 countries worldwide.

  • PR Newswire 23 days ago

    Varian Announces Third Quarter Fiscal Year 2019 Earnings Release Date

    PALO ALTO, Calif. , June 26, 2019 /PRNewswire/ -- Varian (NYSE: VAR) today announced its third quarter fiscal year 2019 earnings release date. The Company will report results for the third quarter of fiscal ...

  • PR Newswire 23 days ago

    Varian to Provide Mobile Technology to Cancer Patients Across Tennessee

    Collaboration with Tennessee Oncology Aims to Improve Access to Care Across Rural Patient Populations PALO ALTO, Calif. , June 26, 2019 /PRNewswire/ -- Providing cancer patients an opportunity for increased ...

  • PR Newswire last month

    Varian Completes Acquisition of Cancer Treatment Services International

    PALO ALTO, Calif. , June 17, 2019 /PRNewswire/ -- Varian (NYSE: VAR) today announced it has successfully completed its acquisition of Cancer Treatment Services International (CTSI). There were no changes ...

  • PR Newswire last month

    Varian to Deliver Six Technical Presentations at ICCR

    PALO ALTO, Calif. , June 13, 2019 /PRNewswire/ -- Varian (NYSE: VAR) today announced it will be delivering presentations focused on artificial intelligence (AI),   federated data sources and clinical decision ...

  • PR Newswire last month

    Varian Medical Systems Presents Latest Innovations in Radiotherapy at DEGRO 25

    MÜNSTER, Germany, June 12, 2019 /PRNewswire/ -- Varian (VAR) will showcase and discuss its latest innovations in radiotherapy at the DEGRO 25 (German Society for Radio Oncology) meeting in Münster, Germany, June 13-16. At the core of the company's DEGRO 25 meeting activities is its Halcyon™ radiotherapy system, which has gone live at seven treatment centers in Germany. During a lunch symposium on June 14 (time and location: see below), Dr. Johannes Gollrad from Charité Universitätsmedizin Berlin as well as Prof. Dr. Florian Würschmidt and Dr. Matthias Kretschmer from Radiologische Allianz Hamburg will discuss their experience with Halcyon.

  • PR Newswire last month

    Varian to Demonstrate New Bravos Afterloader System at ABS 2019

    PALO ALTO, Calif. , June 11, 2019 /PRNewswire/ -- Varian (NYSE: VAR) announced it will be showcasing its Bravos ™ afterloader system for High Dose Rate (HDR) brachytherapy treatments and other advanced ...

  • PR Newswire last month

    Varian Expands Cancer Care Solutions Portfolio with Interventional Oncology Acquisitions

    PALO ALTO, Calif., June 10, 2019 /PRNewswire/ -- Varian (VAR) today announced it has acquired Austin, Texas-based Endocare and Hangzhou, China-based, Alicon, to expand its portfolio of multidisciplinary integrated cancer care solutions.

  • PR Newswire last month

    Herlev University Hospital Treats First Patient in Denmark on Varian Halcyon System

    PALO ALTO, Calif. and HERLEV, Denmark, June 10, 2019 /PRNewswire/ -- Varian (VAR) today announced Herlev University Hospital near Copenhagen, Denmark is Scandinavia's first facility to utilize the Halcyon™ system. The first patient treated on the system was a 42-year-old female undergoing treatment for anal cancer.

  • PR Newswire last month

    Varian-equipped New York Proton Therapy Center Opens with Ribbon Cutting Event

    PALO ALTO, Calif. , June 7, 2019 /PRNewswire/ -- Providing access to proton therapy treatment for cancer patients in the tri-state area, the New York Proton Center (NYPC) held a ribbon cutting event yesterday ...

  • PR Newswire last month

    Varian to Host FlashForward Consortium Meeting at PTCOG58

    PALO ALTO, Calif. , June 7, 2019 /PRNewswire/ -- Varian (NYSE: VAR) today announced it will be hosting its second FlashForward ™ Consortium meeting at 12:00pm Tuesday, June 11th at the 58 th annual Particle ...

  • PR Newswire last month

    Varian Showcasing Latest Proton Therapy Systems and Technology at PTCOG Conference 58

    PALO ALTO, Calif. , June 6, 2019 /PRNewswire/ -- Varian (NYSE: VAR) announced it will be showcasing its new ProBeam ®  360° proton therapy system*, June 12 th -15 th in Manchester, United Kingdom at the ...

  • PR Newswire 2 months ago

    Varian to Showcase Software Solutions at ASCO Annual Meeting

    PALO ALTO, Calif. , May 29, 2019 /PRNewswire/ -- Varian (NYSE: VAR) today announced it will be showcasing its Noona ®  patient management system and its 360 Oncology™ care management platform, May 31-June ...

  • PR Newswire 2 months ago

    Varian Eclipse User Takes Top Spot in 2019 TROG Pancreas Treatment Plan Study

    PALO ALTO, Calif. , May 28, 2019 /PRNewswire/ -- Varian (NYSE: VAR) today announced a physicist using Varian's Eclipse ™ treatment planning system achieved the top overall score in the TROG 2019 Stereotactic ...

  • PR Newswire 2 months ago

    Varian Announces Definitive Agreement to Acquire Cancer Treatment Services International

    PALO ALTO, Calif., May 20, 2019 /PRNewswire/ -- Taking an important step to accelerate innovation of new multidisciplinary solutions to address the growing global cancer burden, Varian Medical Systems (VAR) today announced it has entered into a definitive agreement to acquire Cancer Treatment Services International (CTSI) for $283 million. Privately held, CTSI operates the American Oncology Institute in Hyderabad and 10 multidisciplinary—radiation, medical and surgical oncology— cancer centers across the Indian subcontinent as well as a U.S.-based Oncology Solutions division that provides cancer care professional services to healthcare providers worldwide.

  • PR Newswire 2 months ago

    Varian Announces Incremental Gross Impact of New Tariffs

    PALO ALTO, Calif., May 16, 2019 /PRNewswire/ -- Varian (VAR) today announced preliminary estimates of the incremental gross impact of new tariffs. Over the past week, the US increased tariffs on certain goods (US List 3), and imposed new tariffs on certain other goods (US List 4), imported from China.  Subsequently, China implemented a retaliatory increase in tariffs on certain goods imported from the US (responding to the US List 3 action).  Management has preliminarily estimated the gross impact of these new tariffs to be in the range of $3M to $5M.

  • PR Newswire 2 months ago

    Cyclotron for Varian ProBeam Compact Proton Therapy System Installed at New Treatment Center in Singapore

    The cyclotron is a core piece of equipment in the ProBeam proton therapy system. This installation marks a key milestone for the first proton therapy center in Singapore, ASEAN, Australia and New Zealand.

  • PR Newswire 2 months ago

    Papua New Guinea Hospital Selects Varian Cancer Care Solution

    PALO ALTO, Calif., May 13, 2019 /PRNewswire/ -- Varian (VAR) today announced it was selected by Port Moresby General Hospital (PMGH) in Papua New Guinea to equip its cancer treatment center with the Halcyon™ radiotherapy system, as well as the ARIA® oncology information system and Eclipse™ treatment planning system. The Halcyon system simplifies and enhances virtually every aspect of image-guided volumetric intensity-modulated radiotherapy (IMRT), including improved patient comfort and shortening the time from installation to first-treatment without sacrificing quality. The Halcyon system is well-suited to treat a majority of cancer patients, offering advanced treatments for lung, prostate, breast, head & neck, and many other forms of cancer.

  • PR Newswire 2 months ago

    Varian Acquires CyberHeart

    The CyberHeart acquisition secures significant intellectual property/patents that cover the use of radiation in the heart. Early positive clinical evidence suggests that cardiac radioablation has the potential to offer hope to patients with intractable cardiac arrhythmias. Acquisitions are a critical step in Varian's long-term strategy to become a global leader in multi-disciplinary, integrated cancer solutions as well as other applications of radiation medicine.

  • PR Newswire 2 months ago

    Varian Selected to Equip Two Proton Therapy Centers in Norway

    PALO ALTO, Calif. , May 9, 2019 /PRNewswire/ -- Following a comprehensive evaluation by Sykehusbygg HF Norway and regional health authorities, Varian (NYSE: VAR) was selected to equip two proton therapy ...

  • PR Newswire 2 months ago

    Varian and Shandong Cancer Hospital Form Proton Therapy Clinical Application and Research Partnership in China

    PALO ALTO, Calif. and JINAN, China, May 9, 2019 /PRNewswire/ -- Varian (VAR) today announced it has signed a strategic cooperation framework agreement with Shandong Cancer Hospital in China, for proton therapy clinical application and research. The agreement signing ceremony on May 9th in Jinan, China was attended by Professor Yu Jinming, academician of the Chinese Academy of Engineering and president of Shandong Cancer Hospital & Institute, Kolleen Kennedy, president, Proton Solutions and chief growth officer of Varian, and Dr. Zhang Xiao, vice president and head of Varian Greater China.